Reuters logo
BRIEF-Merck provides update on Anacetrapib development program
October 11, 2017 / 9:08 PM / 2 months ago

BRIEF-Merck provides update on Anacetrapib development program

Oct 11 (Reuters) - Merck & Co Inc

* Merck provides update on Anacetrapib development program

* Merck & Co Inc - ‍Decision follows a thorough review of clinical profile of Anacetrapib, including discussions with external experts​

* Merck & Co Inc - ‍Will not submit applications for regulatory approval for Anacetrapib, Merck’s investigational CETP inhibitor​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below